p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Multidrug resistance (MDR) significantly impedes effective osteosarcoma chemotherapy.
• The p53 tumor suppressor gene plays a crucial role in apoptosis, a key mechanism for cancer therapy effectiveness.
• While p53 mutations are common in osteosarcoma, its role in enhancing chemosensitivity in MDR cells remains unclear.

Purpose of the Study:

• To investigate whether overexpressing wild-type p53 can improve chemosensitivity in multidrug-resistant (MDR) osteosarcoma cell lines.
• To determine the impact of wild-type p53 gene transfection on drug sensitivities in osteosarcoma cells with differing intrinsic p53 statuses.
• To elucidate the molecular mechanisms by which p53 influences chemosensitivity in MDR osteosarcoma.

Main Methods:

• Transfection of a plasmid encoding the wild-type p53 gene into two MDR osteosarcoma cell lines: U-2OSR2 (wild-type p53) and KHOSR2 (mutant p53).
• Assessment of p53 overexpression effects on chemosensitivities in both cell lines.
• Analysis of changes in the expression of key proteins, including p21, Bax, and IGF-1r.

Main Results:

• Both cell lines showed increased drug sensitivities following p53 overexpression, though the specific mechanisms differed based on intrinsic p53 status.
• In KHOSR2 (mutant p53) cells, p53 overexpression upregulated pro-apoptotic proteins p21 and Bax.
• In U-2OSR2 (wild-type p53) cells, p53 overexpression significantly downregulated IGF-1r expression.

Conclusions:

• Transfection of wild-type p53 enhances chemosensitivity in human multidrug-resistant osteosarcoma cell lines.
• This chemosensitization is achieved either by inhibiting IGF-1r or by increasing the expression of pro-apoptotic proteins p21 and Bax.
• The specific pathway activated by p53 depends on the cell line's endogenous p53 status, highlighting a potential therapeutic strategy for osteosarcoma.